Molecular mechanisms of Mycobacterium tuberculosis resistance to reserve-series drugs

Abstract

The review presents the data currently available in the literature on the mechanisms responsible for the development of resistance in Mycobacterium tuberculosis to reserve-series drugs, such as prothionamide, ethionamide, kanamycin, amikacin, capreomycin, cycloserine, rifabutin, PAS, and a group of fluoroquinolones.

Keywords

M. tuberculosis / M. tuberculosis / resistance / gene / mutation / prothionamide / ethionamide / kanamycin / amikacin / capreomycin / cycloserine / rifabutin / PAS / fluoroquinolones

References

[1] Кузьмин А. В., Васильева И. А., Черноусова Л. Н. Эффективность химиотерапии деструктивного туберкулеза легких, основанной на результатах экспресс-детекции лекарственной чувствительности к изониазиду и рифампицину тест-системой ТБ-биочип // Пробл. туб. и бол. легких. - 2006. - № 8. - С. 17-23.

[2] Мишин В. Ю., Чуканов В. И., Васильева И. А. К проблеме оптимизации и доказательности современных режимов химиотерапии туберкулеза легких // Пробл. туб. и бол. легких. - 2004. - № 8. - С. 7-11.

[3] Носова Е. Ю., Галкина К. Ю., Маркова О. В. и др. Изучение лекарственной чувствительности Mycobacterium tuberculosis к фторхинолонам путем выявления мутаций в гене gyrA // Пробл. туб. и бол. легких. - 2007. - № 10. - С. 57-60.

[4] Приказ Министерства здравоохранения РФ № 109 от 21 марта 2003 г. О совершенствовании противотуберкулезных мероприятий в Российской Федерации. - М., 2003.

[5] Туберкулез. Патогенез, защита, контроль / Под ред. Барри Р. Блума; пер. с англ. - М., 2002.

[6] Alangaden G. J., Kreiswirth B. N., Aouad A. et al. // Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 1998. - Vol. 42, N 5. - P. 1295-1297.

[7] Aubry A., Veziris N., Cambau E. et al. Novel gyrase mutations in quinolone-resistant and hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes // Antimicrob. Agents Chemother. - 2006. - Vol. 50, N 1. - P. 104-112.

[8] Banerjee A., Dubnau E., Quemard A. et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis // Science. - 1994. - Vol. 263, N 5144. - P. 227- 230.

[9] Baulard A. R., Betts J. C., Endohang-Ndong J. et al. Activation of the pro-drug ethionamide is regulated in mycobacteria // J. Biol. Chem. - 2000. - Vol. 275, N 36. - P. 28326-28331.

[10] Ca'ceres N. E., Harris N. B., Wellehan J. F. et al. Overexpression of the D-Alanine racemase gene confers resistance to D-Cycloserine in Mycobacterium smegmatis // J. Bacteriol. - 1997. - Vol. 179, N 16. - P. 5046-5055.

[11] Chan R. C. Y., Hui M., Chan E. W. C. et al. // Genetic and phenotypic characterization if drug-resistant Mycobacterium tuberculosis isolates in Hong Kong // J. Antimicrob. Chemother. - 2007. - Vol. 59, N 1. - P. 866-873.

[12] Chikamatsu K., Mizuno K., Yamada H., Mitarai S. Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains // Kekkaku. - 2009. - Vol. 84, N 9. - P. 631-633.

[13] David H. L. Resistance to D-Cycloserine in the tubercle bacilli: mutation rate and transport of alanine in parental cells and drug-resistant mutants // J. Bacteriol. - 1971. - Vol. 21, N 5. - P. 888-892.

[14] DeBarber A. E., Mdluli K., Bosman M. et al. Ethionamide activation and sensitivity in multidrug resistant Mycobacterium tuberculosis // Proc. Natl Acad. Sci. USA. - 2000. - Vol. 97, N 17. - P. 9677-9682.

[15] Devasia R. A., Blackman A., May C. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance // J. Antimicrob. Chemother. - 2009. - Vol. 63, N 6. - P. 1173-1178.

[16] Drlica K., Zhao X. DNA Gyrase, Topoisomerase IV, and the 4-Quinolones // Microbiol. Mol. Biol. Rev. - 1997. - Vol. 61, N 3. - P. 377-392.

[17] Engohang-Ndong J., Baillat D., Aumercier M. et al. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator // Mol. Microbiol. - 2004. - Vol. 51, N 1. - P. 175- 188.

[18] Felnagle E. A., Rondon M. R., Berti A. D. et al. Identification of the biosynthetic gene cluster and an additional gene for resistance to the antituberculosis drug capreomycin // J. Antimicrob. Chemother. - 2007. - Vol. 73, N 13. - P. 4162-4170.

[19] Feng Z., Barletta R. G. Roles of Mycobacterium smegmatis D-Alanine: D-Alanine Ligase and D-Alanine Racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-Cycloserine // Antimicrob. Agents Chemother. - 2003. - Vol. 47, N 1. - P. 283-291.

[20] Feuerriegel S., Cox H. S., Zarkua N. et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients, undergoing treatment // Antimicrob. Agents Chemother. - 2009. - Vol. 53, N 8. - P. 3353-3356.

[21] Giannoni F., Iona E., Sementilli F. et al. Evaluation of new line probe assay for rapid identification of gyr A mutations in Mycobacterium tuberculosis // J. Antimicrob. Chemother. - 2005. - Vol. 49, N 7. - P. 2928-2933.

[22] Herr E. B. Jr., Redstone M. O. Chemical and physical characterization of capreomycin // Ann. N. Y. Acad. Sci. - 1966. - Vol. 135. - P. 940-946.

[23] Hillemann D.,* Rusch-Gerdes S., Richter E. Feasibility of the Geno Type MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strain and clinical specimens // J. Clin. Microbiol. - 2009. - Vol. 47, N 6. - P. 1767-1772.

[24] Ji B., Truffot-Pernot C., Lacroix C. et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tubercolosis in mice // Am. Rev. Respir. Dis. - 1993. - Vol. 148. - P. 1541-1546.

[25] Johansen S. K., Maus C. E., Plikaytis B. B., Douthwaite S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 20-O-methylations in 16S and 23S rRNAs // Mol. Cell. - 2006. - Vol. 23. - P. 173-182.

[26] Johnson R., Streicher E. M., Louw G. E. et al. Drug resistance in Mycobacterium tuberculosis // Curr. Issues Mol. Biol. - 2005. - Vol. 8. - P. 97-112.

[27] Jugheli L., Bzekalava N., de Rijk P. et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gent // Antimicrob. Agents Chemother. - 2009. - Vol. 53, N 12. - P. 5064- 5068.

[28] Kocagöz T., Hackbarth C. J., Unsal I. et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra // J. Antimicrob. Chemother. - 1996. - Vol. 40, N 87. - P. 1768-1774.

[29] Koseki Y., Okamoto S. Studies on sross-resistance between capreomycin and certain other antimycobacterial agants // Jpn J. Med. Sci. Biol. - 1963. - Vol. 16. - P. 31-38.

[30] Larsen M. H., Vilchéze C., Kremer L. et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis // Mol. Microbiol. - 2002. - Vol. 46, N 2. - P. 453-466.

[31] Marrakchi H., Laneelle G., Quemard A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II // Microbiology. - 2000. - Vol. 146. - P. 289-296.

[32] Mathys V., Wintjens R., Lefevre P. et al. Molecular genetics of paraaminosalicylie acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2009. - Vol. 53, N 5. - P. 2100-2109.

[33] Maus C. E., Plikaytis B. B., Shinnick T. M. Molecular analysis cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2005. - Vol. 49, N 8. - P. 3192-3197.

[34] Maus C. E., Plikaytis B. B., Shinnick T. M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis // Antimicrob. Agents Chemother. - 2005. - Vol. 49, N 2. - P. 571-577.

[35] McClatchy J. K., Kanes W., Davidson P. T., Moulding T. S. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin // Tubercle. - 1977. - Vol. 58. - P. 29-34.

[36] Mdluli K., Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery // Infect. Disord. Drug Targets. - 2007. - Vol. 7, N 2. - P. 159-168.

[37] Mokrousov I., Otten T., Manicheva O. et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia // Antimicrob. Agents Chemother. - 2008. - Vol. 52, N 8. - P. 2937-2939.

[38] Morlock G. P., Metchock B., Sikes D. et al. EthA, inhA, and katG Loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates // Antimicrob. Agents Chemother. - 2003. - Vol. 47, N 12. - P. 3799-3805.

[39] Peteroy M., Severin A., Zhao F. et al. Characterization of a Mycobacterium smegmatis mutant that is simultaneously resistant to D-Cycloserine and Vancomycin // Antimicrob. Agents Chemother. - 2000. - Vol. 44, N 6. - P. 1701-1704.

[40] Petry Jr. W. Chemotherapy of tuberculosis, mycobacterium avium complex disease and leprosy // Goodman & Gilman The pharmacological Basis of Therapeutics / Brunton L. L. et al. - 2006. - P. 1203-1223.

[41] Pitaksajjakul P., Wongwit W., Punprasit W. et al. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand // Southeast Asian J. Trop. Med. Publ. Hlth. - 2005. - Vol. 36, N 4. - P. 228-237.

[42] Rengarajan J., Sassetti C. M., Naroditskaya V. et al. The folate pathway is a target for resistance to the drug para-aminosalicylie acid (PAS) in mycobacteria // Mol. Microbiol. - 2004. - Vol. 53, N 1. - P. 275-282.

[43] Shi R., Zhang J., Li C. et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing // J. Clin. Microbiol. - 2006. - Vol. 44, N 12. - P. 4566-4568.

[44] Sreevatsan S., Pan X., Stockbauer K. E. et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionary recent global dissemination // Proc. Natl Acal. Sci. USA. - 1997. - Vol. 94. - P. 9869- 9874.

[45] Sugawara I., Zhang J., Li C. Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin // Indian J. Exp. Biol. - 2009. - Vol. 47, N 6. - P. 520-522.

[46] Sun Z., Zhang J., Zhang X. et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates // Int. J. Antimicrob. Agents. - 2008. - Vol. 31. - P. 115-121.

[47] Sutton W. B., Gordee R. S., Wick W. E., Standfield L. V. In vitro and in vivo laboratory studies on the antituberculosis activity of capreomycin // Ann. N. Y. Acad. Sci. - 1966. - Vol. 135. - P. 947-959.

[48] Suzuki Y., Katsukawa C., Tamaru A. et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene // J. Clin. Microbiol. - 1998. - Vol. 36, N 5. - P. 1220-1225.

[49] Taniguchi H., Chang B., Abe C. et al. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system // J. Bacteriol. - 1997. - Vol. 179, N 15. - P. 4795-4801.

[50] Tsukamura M. Cross-resistance relationships between capreomycin, kanamycin and viomycin resistance in tubercle bacilli from patients // Am. Rev. Respir. Dis. - 1969. - Vol. 99. - P. 780-782.

[51] Tyagi J. S., Sharma D. Mycobacterium smegmatis and tuberculosis // Trends Microbiol. - 2002. - Vol. 10, N 2. - P. 68- 69.

[52] Uzun M., Erturan Z. O. An investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains // J. Tuberc. Lung Dis. - 2002. - Vol. 6, N 2. - P. 164-165.

[53] Vilchéze C., Weisbrod T. R., Chen B. et al. Altered NADH/ NAD+ ratio mediates coresistance to isoniazid and ethionamide in Mycobacteria // Antimicrob. Agents Chemother. - 2005. - Vol. 49, N 2. - P. 708-720.

[54] Vilchéze C., Av-Gay Y., Attarian R. et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis // Mol. Microbiol. - 2008. - Vol. 69, N 5. - P. 1316-1329.

[55] Wang J. C. DNA topoisomerases // Annu. Rev. Biochem. - 1985. - Vol. 54. - P. 665-597.

[56] Wang J.-Y., Lee L.-N., Lai H.-C. et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure // J. Antimicrob. Chemother. - 2007. - Vol. 59. - P. 860-865.

[57] Wargel R. J., Shadur C. A., Neuhaus F. C. Mechanism of D-Cycloserine action: transport mutants for D-Alanine, D-Cycloserine, and Glycinel // J. Bacteriol. - 1971. - Vol. 105, N 3. - P. 1028-1035.

[58] Winder F. G., Collins P. B., Whelan D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG // J. Gen. Microbiol. - 1971. - Vol. 68. - P. 1037-1044.

[59] Xu P., Li X., Zhao M. et al. Prevalence of fluoroquiolone resistance among tuberculosis patients in Shanghai, China // J. Antimicrob. Chemother. - 2009. - Vol. 53, N 7. - P. 3170-3172.

[60] Yang B., Koga H., Ohno H. et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis // J. Antimicrob. Chemother. - 1998. - Vol. 42, N 5. - P. 621-628.

[61] Zhang Y. The magic bullets and tuberculosis drug targets // Annu. Rev. Pharmacol. Toxicol. - 2005. - Vol. 45. - P. 529- 564.

RIGHTS & PERMISSIONS

Eco-vector